Literature DB >> 17698142

Androgen deprivation therapy for prostate cancer.

Robert Bahnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17698142     DOI： 10.1016/j.juro.2007.07.066

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  5 in total

1.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

2.  Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells.

Authors:  Siqi Xu; Xiaoyan Wu; Zhihua Tao; Hongsheng Li; Chenliang Fan; Songjin Chen; Jianwei Guo; Yao Ning; Xuqi Hu
Journal:  Genes Genomics       Date:  2019-12-23       Impact factor: 1.839

3.  Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

Authors:  N Olea-Herrero; D Vara; S Malagarie-Cazenave; I Díaz-Laviada
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

Review 4.  Selective androgen receptor modulators in preclinical and clinical development.

Authors:  Ramesh Narayanan; Michael L Mohler; Casey E Bohl; Duane D Miller; James T Dalton
Journal:  Nucl Recept Signal       Date:  2008-11-26

5.  Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer.

Authors:  Linyan Chen; Qingfang Li; Yexiao Wang; Yiwen Zhang; Xuelei Ma
Journal:  Oncotarget       Date:  2017-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.